BioDelivery Sciences International's BEMA(TM) Fentanyl NDA Submission Remains on Target for Third Quarter Following Meeting With FDA

MORRISVILLE, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq:BDSI) announced that its June 28, 2007 pre-NDA (New Drug Application) meeting with the FDA regarding the company’s Phase III BEMATM Fentanyl product went according to plan and was viewed by the company as a positive development. Based on the discussion with the FDA at the meeting, BDSI continues to project an NDA submission for its “breakthrough” cancer pain product, BEMATM Fentanyl, during the third quarter of 2007.